BioDelivery (BDSI) Receives U.S. Patent for BEMA Products; Gets $15M Milestone
Tweet Send to a Friend
Up)
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that the U.S. Patent and Trademark Office (USPTO) has formally awarded BDSI's patent No. 13/184306, "Transmucosal Delivery Devices with Enhanced Uptake," which extends the patent protection for BDSI's BioErodible MucoAdhesive (BEMA) products, BEMA Buprenorphine and BEMA Buprenorphine/Naloxone, by seven years to 2027. The USPTO had issued a Notice of Allowance to BDSI for this patent as previously disclosed in February of this year.
BDSI now confirms that the $15 million milestone associated with its licensing and development agreement with Endo Pharmaceuticals (Nasdaq: ENDP) for BEMA Buprenorphine is payable, bringing the total milestone payments received thus far to $45 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
BDSI now confirms that the $15 million milestone associated with its licensing and development agreement with Endo Pharmaceuticals (Nasdaq: ENDP) for BEMA Buprenorphine is payable, bringing the total milestone payments received thus far to $45 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Merck (MRK) Says Efficacy Not Achieved in Preladenant Phase 3s; Will Discontinue
- Gleacher & Co. (GLCH) Reports Election of Five for Board Members
- Janssen Pharma (JNJ) Plans Slew of Filing, Extension Submissions by FY17
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
